Výsledky vyhledávání - "B Mavromatis"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abstract P2-14-11: Treatment recommendations in ER+ patients ≤ 50 years: Comparison of the 21-gene assay and 70-gene signature in the PROMIS study

Autor: Lisa Blumencranz, Raye Budway, Michaela Tsai, Robin Zon, Joseph McKelley, Rubina Qamar, Hatem Soliman, Sarah Untch, B Mavromatis, Shelly S. Lo, Pat Whitworth, William Audeh, Ellis G. Levine

Publikováno v: Cancer Research. 80:P2-14

Background: The PROMIS trial (NCT01617954) previously evaluated how a definitive result from the MammaPrint 70-gene signature (70-GS) can impact treatment recommendations for patients with an intermediate range recurrence score (RS 18-30) from the 21

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a96c27b8b2c134ce197434de4e04d307
https://doi.org/10.1158/1538-7445.sabcs19-p2-14-11

Zobrazit plný text záznamu

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

Autor: William Audeh, Varsha Shah, Rubina Qamar, Ellis G. Levine, Gordan Srkalovic, Reshma Mahtani, Sarah Untch, Heather M. Kling, Robert Gabordi, B Mavromatis, Tina Treece, Hatem Soliman, Mohamad Kassar, Jayanthi Srinivasiah

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer

Background Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence based on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b653e133220532b332a9ed5fb8fb852a
https://doaj.org/article/87a37eaf5e5243ac9fe1d0dcb516b31f

Zobrazit plný text záznamu

Plný text ve formátu HTML

Abstract OT1-13-01: MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX)

Autor: Erin Yoder, P Baron, Lisa Blumencranz, Thomas Lomis, Adam Brufsky, Gordan Srkalovic, Sarah Untch, Jennifer A. Crozier, Peter W. Blumencranz, P Whitworth, E Rehmus, William Audeh, B Mavromatis, LL Lee, Ian Grady

Publikováno v: Cancer Research. 79:OT1-13

BACKGROUND: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer subtypes. The ability of genomic signatures to enable fine grained stratification of breast cancers to the granular disease level is sti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26a0584f8d7e31d63f0b7eb59445164e
https://doi.org/10.1158/1538-7445.sabcs18-ot1-13-01

Zobrazit plný text záznamu

Abstract P4-08-10: MammaPrint identifies 46% of patients, age ≤50 years with oncotype RS 18-30, as low risk and safe to forgo chemotherapy

Autor: H Soliman, S Lo, R Qamar, R Budway, E Levine, P Whitworth, B Mavromatis, R Zon, S Untch, T Treece, L Blumencranz, W Audeh, M Tsai, Group PROMIS Investigators

Publikováno v: Cancer Research. 79:P4-08

Background: The PROMIS trial (NCT01617954) previously showed that an OncotypeDx (ODx) Intermediate Recurrence Score (RS 18-30) led to uncertainty in prescribing chemotherapy (CT), especially in the middle of the intermediate range from RS 21-26 where

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7b00cf2d7ee08efc5acb1c37b2d3af0
https://doi.org/10.1158/1538-7445.sabcs18-p4-08-10

Zobrazit plný text záznamu

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer

Autor: J Srinivasiah, Reshma Mahtani, Hatem Soliman, B Mavromatis, Erin Yoder, M Kassar, Gordan Srkalovic, William Audeh, Ellis G. Levine, V Shah, R Gabordi, E Rehmus, Rubina Qamar

Publikováno v: Cancer Research. 78:P6-13

Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with his

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d537c9186d639722932528732bef472c
https://doi.org/10.1158/1538-7445.sabcs17-p6-13-04

Zobrazit plný text záznamu

Abstract PD7-04: Metabolic syndrome increases risk of recurrence and impacts immune pathways in invasive lobular carcinoma

Autor: P Robinson, T Treece, C Osipo, S Uygun, H Kling, R Qamar, R Zon, E Levine, R Budway, B Mavromatis, S Untch, R Bernards, W Audeh, H Soliman, Group IMPACt Investigators

Publikováno v: Cancer Research. 79:PD7-04

Background: Invasive lobular carcinoma (ILC) of the breast has been shown to be more strongly associated with risk factors that modulate hormone levels, including obesity, as compared with invasive ductal carcinoma (IDC). Our previous study indicated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cf0a1e57e25431741b0afca6614385e9
https://doi.org/10.1158/1538-7445.sabcs18-pd7-04

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání